Abstract: Objective: To study the effects of intrahepatic arterial infusion of rh -endostatin (YH -16, Endostar) combined with transcatheter arterial chemoembolization (TACE) for treatment of advanced hepatocellular carcinoma. Methods: Thirty patients with advanced hepatocellular carcinoma who underwent intrahepatic arterial infusion of Endostar combined with TACE were enrolled in the study. The effects were evaluated after 1~2 cycles according to response evaluation criteria in solid tumors (RECIST) and the value of AFP was observed. Quality of life was assessed according toKarnofsky scoring. Results: Twenty-nine out of the 30 cases were evaluable. Karnofsky scores were significantly increased after the treatment (80.39± 8.37 vs. 73.93± 9.22, P=0.002). Compared with the control group, the overall response rate (CR and PR) and the rate of reversion to normal AFP expression were higher in the group treated with Endostar combined with TACE (P=0.021, P=0.046). No obvious adverse effects were observed. Conclusion: With few adverse effects, trancatheter arterial infusion of Endostar combined with TACE can improve the quality of life for patients with advanced hepatocellular carcinoma, and it can increase the rate of reversion to negative AFP expression. This treatment is worthy of clinical generalization and further clinical observation.